Work

Abstract CT288: First-in-human study of oral PARG inhibitor SYN608 in advanced solid tumors

Year: 2026

Type: conference-abstract

Source: Cancer Research

DOI: 10.1158/1538-7445.am2026-ct288

Institutions: Fudan University Shanghai Cancer Center, Shandong First Medical University, Tianjin Medical University Cancer Institute and Hospital, Tianjin Medical University, Zhejiang Cancer Hospital

Language: English

Topic: PARP inhibition in cancer therapy

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W7154723241

Cites:

Cited by:

Related to: